Publication of the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) late in 2022 followed by just 2 years KDIGO's original guideline on this clinical area published in 2020. Motivation for the update, according to the writing group, came from the "wealth of high quality new evidence" that has become so rapidly available since the 2020 iteration as well as from the growing need for guidance to apply the plentiful new data.
The majoirty of the new evidence relates to the cardiorenal protective benefits of 3 drug classes in particular: sodium-glucose co-transporter-2 inhibitors (SGLT2i), the glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the new class of nonsteroidal mineralocorticoid receptor antagonists (MRA). Guideline Chapters 1 (Comprehensive care) and 4 (Glucose-lowering therapies) were revised for the use of SGLT2i and GLP-1 RA, and a new section was developed. for the nonsteroidal MRA.
For this Guideline Topline, the editors chose to highlight the new recommendations and practice points related to clinical use of these 3 drug classes in perons with diabetes and chronic kidney disease (CKD) and to summarize the writing committee's rationale. Click through.
Reference: Boer IH, Rossing P, Chan JCN, et al. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102 (Suppl 5S), S1–S127. doi:10.1016/j.kint.2022.06.013